Generic version of Vfend now available

December 19, 2013

Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc., has introduced voriconazole for oral suspension, an authorized generic version of Vfend.

Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc., has introduced voriconazole for oral suspension, an authorized generic version of Vfend.

The antifungal agent will be offered in a dosage strength of 40 mg/mL. Voriconazole (Vfend, Pfizer) was approved for use in the treatment of invasive aspergillosis and the treatment of serious fungal infections caused by Scedosporium apiospermum and Fusarium spp in patients intolerant of, or refractory to, other therapy.

Full prescribing information is available here.